Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, Wang L, Dong L, Setiady Y, Maloney EK, Ab O, Zhang X, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM. Sun X, et al. Among authors: yoder nc. Bioconjug Chem. 2017 May 17;28(5):1371-1381. doi: 10.1021/acs.bioconjchem.7b00062. Epub 2017 Apr 13. Bioconjug Chem. 2017. PMID: 28388844
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML, Shizuka M, Wilhelm A, Salomon P, Reid EE, Lanieri L, Sikka S, Maloney EK, Harvey L, Qiu Q, Archer KE, Bai C, Vitharana D, Harris L, Singh R, Ponte JF, Yoder NC, Kovtun Y, Lai KC, Ab O, Pinkas J, Keating TA, Chari RVJ. Miller ML, et al. Among authors: yoder nc. Mol Cancer Ther. 2018 Mar;17(3):650-660. doi: 10.1158/1535-7163.MCT-17-0940. Epub 2018 Feb 13. Mol Cancer Ther. 2018. PMID: 29440292
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C, Reid EE, Wilhelm A, Shizuka M, Maloney EK, Laleau R, Harvey L, Archer KE, Vitharana D, Adams S, Kovtun Y, Miller ML, Chari R, Keating TA, Yoder NC. Bai C, et al. Among authors: yoder nc. Bioconjug Chem. 2020 Jan 15;31(1):93-103. doi: 10.1021/acs.bioconjchem.9b00777. Epub 2019 Dec 10. Bioconjug Chem. 2020. PMID: 31747250 Free article.
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs).
Reid EE, Archer KE, Shizuka M, Wilhelm A, Yoder NC, Bai C, Fishkin NE, Harris L, Maloney EK, Salomon P, Hong E, Wu R, Ab O, Jin S, Lai KC, Sikka S, Chari RVJ, Miller ML. Reid EE, et al. Among authors: yoder nc. ACS Med Chem Lett. 2019 Jul 10;10(8):1193-1197. doi: 10.1021/acsmedchemlett.9b00240. eCollection 2019 Aug 8. ACS Med Chem Lett. 2019. PMID: 31413805 Free PMC article.
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.
Catcott KC, McShea MA, Bialucha CU, Miller KL, Hicks SW, Saxena P, Gesner TG, Woldegiorgis M, Lewis ME, Bai C, Fleming MS, Ettenberg SA, Erickson HK, Yoder NC. Catcott KC, et al. Among authors: yoder nc. MAbs. 2016;8(3):513-23. doi: 10.1080/19420862.2015.1134408. Epub 2016 Jan 11. MAbs. 2016. PMID: 26752675 Free PMC article.
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, Lanieri L, Bogalhas M, Wang L, Wilhelm S, Widdison W, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM. Ponte JF, et al. Among authors: yoder nc. Bioconjug Chem. 2016 Jul 20;27(7):1588-98. doi: 10.1021/acs.bioconjchem.6b00117. Epub 2016 Jun 20. Bioconjug Chem. 2016. PMID: 27174129
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation.
Yoder NC, Bai C, Tavares D, Widdison WC, Whiteman KR, Wilhelm A, Wilhelm SD, McShea MA, Maloney EK, Ab O, Wang L, Jin S, Erickson HK, Keating TA, Lambert JM. Yoder NC, et al. Mol Pharm. 2019 Sep 3;16(9):3926-3937. doi: 10.1021/acs.molpharmaceut.9b00529. Epub 2019 Jul 31. Mol Pharm. 2019. PMID: 31287952
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D. Scribner JA, et al. Among authors: yoder nc. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059. doi: 10.1158/1535-7163.MCT-21-0915. Mol Cancer Ther. 2022. PMID: 35511740
27 results